See if TUL321 is safe and tolerable in healthy adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This first-in-human trial investigates the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and repeated oral doses of TUL321 in healthy participants. It also assesses how a high-fat meal changes PK and includes an evaluation of the drug's effect on QT/QTc intervals. The study uses a randomized design with TUL321 and placebo groups across two parts, and monitors biotransformation and mass balance after dosing. Primary goals focus on safety and tolerability, with secondary aims to map PK/PD profiles and potential food effects. The trial is conducted at a single site and overseen by the lead sponsor Zhuhai United Laboratories Co., Ltd.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Participants can communicate well with investigators, fully understand the study, volunteer to take part, comply with all study requirements, and sign written informed consent before study procedures.
2. Age 18-45 years (inclusive) at informed consent, male or female.
3. Weight ≥50.0 kg for males, ≥45.0 kg for females; BMI 19.0-26.0 kg/m² (inclusive).
4. Female participants with child-bearing potential, and male participants whose partners have child-bearing potential: no pregnancy, sperm or egg donation from consent to 3 months after last dose, and willing to use study-required contraception.
5. For MAD-only participants: receive ACYW135 meningococcal vaccine and pneumococcal vaccine at least 14 days before first dose. No re-vaccination is needed if pneumococcal vaccine was given within 5 years, or ACYW135 meningococcal vaccine within 3 years prior to first dose.

Exclusion Criteria:

1. Suspected or confirmed allergy to investigational product or its similar components; or history of multiple drug/food allergies.
2. Past history of tuberculosis infection or active tuberculosis at screening.
3. Known or suspected history of immunodeficiency, inherited or acquired complement deficiency.
4. Confirmed active systemic bacterial, viral or fungal infection within 2 weeks before screening.
5. History of confirmed encapsulated bacterial infection within 6 months before screening, including but not limited to meningococcus, streptococcus pneumoniae, Haemophilus influenzae type b.
6. Clinically significant abnormal findings in laboratory tests, physical examination, vital signs, ECG, chest X-ray or abdominal ultrasound at screening.
7. QTcF (Fridericia correction) ≥450 ms at screening; or other risk factors for torsades de pointes (TdP), such as heart failure, hypokalemia, hypomagnesemia, family history of long QT syndrome.
8. eGFR \<90 mL/min/1.73 m² (calculated by CKD-EPI formula) at screening.
9. Positive for HBsAg, anti-HCV, anti-HIV or syphilis-specific antibody at screening.
10. Received other vaccines not specified in the protocol within 1 month before screening, or plan to receive such vaccines during the study.
11. Participated in another interventional clinical trial within 3 months before screening (excluding subjects who only completed screening without enrollment, or enrolled but did not receive study treatment).
12. Average daily cigarette consumption \>5 cigarettes within 3 months before screening.
13. History of drug/substance abuse within 6 months before screening, or positive drug abuse screening test.
14. Chronic constipation or diarrhea, or other conditions judged by investigator to interfere with fecal sample collection.
15. Required or plan to perform heavy physical labor or strenuous exercise during study participation.
16. Pregnant or lactating women, or women of child-bearing potential with positive pregnancy test at screening.
17. Acute illness or concomitant medication occurs from screening to pre-first-dose.
18. Cannot tolerate high-fat meal (applies only to subjects in the food-effect sub-study).
19. Difficulty swallowing, intolerance to venipuncture, or history of needle-syncope or blood-syncope.
20. Investigator judges that the subject is unsuitable for this study for any other reason.

Where it's running

• Third Xiangya Hospital of Central South University
  Changsha, Hunan, China Recruiting

Study contacts

• Principal investigator: Guoping Yang — The Third Xiangya Hospital of Central South University
• Study coordinator: Guoping Yang
• Email: ygp9880@163.com
• Phone: +86-13974817168

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding congenital bone marrow failure and related disorders through a national network

  This project tests whether people with rare inherited bone marrow failure syndromes or related conditions really have the underlying genetic causes, by collecting data and samples across multiple centers.

  Recruiting at 4 sites Istituto Giannina Gaslini · Avellino and 3 other locations · NCT07877727

• CMS-D017 capsules: single and multiple dose testing in healthy adults

  This trial will test CMS-D017 capsules in healthy Chinese adults to see if single and multiple oral doses are safe and how the drug behaves in the body.

  Recruiting Phase 1 Shenzhen Kangzhe Biotechnology Co., Ltd. · Beijing · NCT07462780

• Real-world use of iptacopan for PNH in Italy

  This project will see if iptacopan works and is safe for adults with paroxysmal nocturnal hemoglobinuria (PNH) who are treated in Italian clinics.

  Recruiting at 12 sites Novartis · Alessandria, AL and 11 other locations · NCT07229235

• ALN-CFB for adults with PNH who remain anemic on C5 inhibitors

  This trial will test ALN-CFB, an experimental siRNA medicine, versus placebo in adults with PNH who remain anemic despite taking a C5 inhibitor.

  Recruiting at 8 sites Phase 1/2 Regeneron Pharmaceuticals · Toronto, Ontario and 7 other locations · NCT07187401

• How HSK39297 is processed and tolerated in people with mild to moderate liver impairment

  This trial tests how the drug HSK39297 is absorbed, cleared, and tolerated in adults with mild to moderate liver impairment compared with people who have normal liver function.

  Recruiting Phase 1 Haisco Pharmaceutical Group Co., Ltd. · Beijing · NCT07152288

• Iptacopan for children and teens with PNH to see how the drug behaves in the body and whether it is safe

  This trial will try oral iptacopan in children and teens (ages 2 to under 18) with PNH to see how their bodies handle the drug and whether it is safe and well tolerated.

  Recruiting at 15 sites Phase 3 Novartis · Atlanta, Georgia and 14 other locations · NCT06934967

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.